Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Pfizer To Acquire Medivation in $14 Billion Deal

XTALKS VITALS NEWS

Acquisition

The winning bid is worth a staggering $81.50 per share, surprising analysts who thought that $75 would be the ceiling.

Tweetables from this article:

Tweet: Medivation has accepted Pfizer’s $14 billion bid to acquire the company, after a months-long process http://ctt.ec/xdGUu+Medivation has accepted Pfizer’s $14 billion bid to acquire the company, after a months-long process.

Tweet: Last year, Medivation’s PARP inhibitor, talazoparib, was projected to bring in $200 million at its peak http://ctt.ec/6u3e7+Last year, Medivation’s PARP inhibitor, talazoparib, was projected to bring in $200 million at its peak.

Share this!

August 23, 2016 | by Sarah Massey, M.Sc.

Medivation has accepted Pfizer’s $14 billion bid to acquire the company, after a months-long process involving other bidders. The company was originally approached by Sanofi whose initial bid was $9.3 billion.

The winning bid is worth a staggering $81.50 per share, surprising analysts who thought that $75 would be the ceiling. Although Sanofi was the only other company to officially confirm their interest in acquiring the biopharmaceutical company, some have speculated that Pfizer beat out a number of other contenders, including Celgene, Merck and Gilead.

“The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer,” said Ian Read, chairman and CEO of Pfizer. “The addition of Medivation will strengthen Pfizer’s Innovative Health business and accelerate its pathway to a leadership position in oncology, one of our key focus areas, which we believe will drive greater growth and scale of that business over the long-term.



“This transaction is another example of how we are effectively deploying our capital to generate attractive returns and create shareholder value.” According to a statement released by Pfizer, the agreement is an all-cash deal.

Medivation’s blockbuster prostate cancer drug, Xtandi (Astellas), and its Phase III PARP inhibitor oncology drugs were major factors in the bidding war. The acquisition represents a significant boost for Pfizer, after its record-breaking deal with Allergan fell through earlier this year.

Last year, Medivation’s PARP inhibitor, talazoparib, was projected to bring in $200 million at its peak. Also in the company’s pipeline are the blood cancer drug, pidilizumab, currently being tested in a Phase II clinical trial, as well as a bladder cancer drug candidate, and a multiple myeloma therapy – both of which are in the early stages of development.

“We believe the combination with Pfizer is the right next step in our growth trajectory and is a testament to the passion and dedication by which the Medivation team has delivered on our mission to profoundly transform patients’ lives through medically innovative therapies,” said Dr. David Hung, founder, president and CEO of Medivation. “We believe that Pfizer is the ideal partner to extend the reach of our blockbuster Xtandi franchise and take our promising, late-stage assets – talazoparib and pidiluzimab – to their next stages of development so that they can be made available to patients as quickly as possible.”


Keywords: Acquisition, Biopharmaceutical, Pipeline


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
GSK Malaria Vaccine to be Pilot Tested in Three African Countries

April 25, 2017 - Ghana, Kenya and Malawi will become the first countries to test GlaxoSmithKline’s (GSK) malaria vaccine in 2018.

Featured In: Life Science News


AbbVie Posts Late-Stage Clinical Trial Results for Chronic Hepatitis C Drug

April 24, 2017 - Patients with a traditionally challenging to treat subtype of hepatitis C may soon have a new treatment option for the chronic infection.

Featured In: Clinical Trials News


Study: Few Cardiovascular Benefits of Aspirin Therapy for Patients with Peripheral Vascular Disease

April 24, 2017 - A new study conducted by researchers at the University of Florida has found that aspirin therapy may not provide sufficient cardiovascular benefits for patients with peripheral vascular disease.

Featured In: Clinical Trials News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

A Holistic Understanding of the Patient Journey Using Multiple Data Sources


Addressing the Challenges of Type II Diabetes Global Clinical Trials via Use of High Quality Laboratory Solutions


Clinical Trial Considerations in Cerebral Protection for TAVR Patients


Enabling Multi-Analyte Analysis of Lung Cancer FFPE Samples with 3D Biology™ Technology


Copyright © 2016-2017 Honeycomb Worldwide Inc.